Literature DB >> 25131506

The effects of curcumin on depressive-like behavior in mice after lipopolysaccharide administration.

Zhen Wang1, Qingrui Zhang2, Lin Yuan2, Shuanglian Wang2, Liwei Liu3, Xudong Yang2, Gang Li4, Dexiang Liu5.   

Abstract

Current evidence supports that inflammation and increased cytokine levels are associated with depression-like symptoms and neuropsychological disturbances in humans. Curcumin has anti-inflammatory, antioxidant and anti-depressant-like properties. Here, we examined the effects of curcumin on lipopolysaccharide (LPS)-induced depressive-like behavior and inflammation in male mice. A single administration of LPS (0.83mg/kg, i.p.) increased the immobility time in the forced swimming test (FST) and tail suspension test (TST), reduced sucrose consumption without affecting spontaneous locomotor activity. Pretreatment with curcumin (50mg/kg, i.p.) for 7 consecutive days reversed LPS-induced alterations in the FST, TST, and sucrose preference test. Moreover, pre-treatment with curcumin attenuated LPS-induced microglial activation and overproduction of pro-inflammatory cytokine (interleukin-1β and tumor necrosis factor-α), as well as the levels of inducible nitric oxide synthase and cyclooxygenase-2 mRNA in the hippocampus and prefrontal cortex (PFC). In addition, curcumin ameliorated LPS-induced NF-κB activation in the hippocampus and PFC. The results demonstrate that curcumin may be an effective therapeutic agent for LPS-induced depressive-like behavior, partially due to its anti-inflammatory aptitude.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Curcumin; Depression; Lipopolysaccharide; NF-κB; Pro-inflammatory cytokines

Mesh:

Substances:

Year:  2014        PMID: 25131506     DOI: 10.1016/j.bbr.2014.08.018

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  22 in total

1.  Gentiopicroside abrogates lipopolysaccharide-induced depressive-like behavior in mice through tryptophan-degrading pathway.

Authors:  Ya-Ting Deng; Ming-Gao Zhao; Tian-Jiao Xu; Xin-Hua Li
Journal:  Metab Brain Dis       Date:  2018-06-15       Impact factor: 3.584

2.  Tetramethylpyrazine ameliorates depression by inhibiting TLR4-NLRP3 inflammasome signal pathway in mice.

Authors:  Songnian Fu; Jiangtao Wang; Chenguang Hao; Haihong Dang; Sheng Jiang
Journal:  Psychopharmacology (Berl)       Date:  2019-03-07       Impact factor: 4.530

Review 3.  Duality of Antidepressants and Neuroprotectants.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2015-11-27       Impact factor: 3.911

Review 4.  Role of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches.

Authors:  Robert Dantzer
Journal:  Curr Top Behav Neurosci       Date:  2017

5.  What Animal Models Can Tell Us About Long-Term Psychiatric Symptoms in Sepsis Survivors: a Systematic Review.

Authors:  Felipe Dal-Pizzol; Gabriela Ferreira de Medeiros; Monique Michels; Aurélien Mazeraud; Fernando Augusto Bozza; Cristiane Ritter; Tarek Sharshar
Journal:  Neurotherapeutics       Date:  2021-01-06       Impact factor: 7.620

6.  The effects of EGb761 on lipopolysaccharide-induced depressive-like behaviour in C57BL/6J mice.

Authors:  Yuehan Zhao; Yongdong Zhang; Fang Pan
Journal:  Cent Eur J Immunol       Date:  2015-04-22       Impact factor: 2.085

7.  EGb761 attenuates depressive-like behaviours induced by long-term light deprivation in C57BL/6J mice through inhibition of NF-κB-IL-6 signalling pathway.

Authors:  Yongdong Zhang; Yuehan Zhao; Fang Pan; Panmin Zhang
Journal:  Cent Eur J Immunol       Date:  2017-01-24       Impact factor: 2.085

Review 8.  LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals.

Authors:  Miryam Nava Catorce; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 9.  Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery.

Authors:  Jennifer L Remus; Robert Dantzer
Journal:  Int J Neuropsychopharmacol       Date:  2016-09-21       Impact factor: 5.176

10.  Behavioral effects of mefloquine in tail suspension and light/dark tests.

Authors:  John Michael Holden; Richard Slivicki; Rachel Dahl; Xia Dong; Matt Dwyer; Weston Holley; Crissa Knott
Journal:  Springerplus       Date:  2015-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.